Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05569187
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ribociclib — DRUG
    Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year

Study Details

Observational, longitudinal (retrospective cohort), multicenter, national study aiming to evaluate the proportion of women with HR+/HER2- advanced breast cancer treated with ribociclib plus non-steroidal aromatase inhibitors who were alive and without disease progression at 1 year.

Key Dates

Start date
Mar 23, 2021
Status verified
Nov 2022
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021

Study Design

Enrollment
76 participants (actual)

Arms

  • Arm: Ribociclib in combination with non-steroidal aromatase inhibitors
    Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year

Primary Outcome Measure

Proportion of patients alive and progression-free from disease at 1 year [ Time Frame: 1 year post-treatment ]

Related Studies